Biogen’s collaboration with Genentech could pay off again in the form of US royalties for the potential blood cancer drug glofitamab, a CD20xCD3 bispecific.
Biogen will receive tiered royalties on potential net sales of glofitamab within the US and will have no payment obligations — if the drug gets approved....
